Orion Corporation develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Orion has been building well-being for over 90 years.

Orion as a listed company

Orion’s Shares A and B are quoted on the NASDAQ OMX Helsinki in the Large

Cap group under the Healthcare sector heading. Trading in both of the company’s

share classes commenced on 3 July 2006 under the trading codes ORNAV

and ORNBV. Information on trading in the company’s shares has been available

since this date. 

Clientele 

Pharmaceuticals business 

Pharmaceuticals account for about 95% of Orion’s net sales, of which a considerable part comes from proprietary patented pharmaceutical innovations.

The core therapy areas in Orion’s product and research strategy are:

• central nervous system
• oncology and critical care
• respiratory medicines administered with the Easyhler device.

Orion has also a large portfolio of generic, off-patent prescription medicines, hospital treatments and self-care products. These products are sold mainly in Finland, other Nordic countries, the new EU countries and Germany.

In animal health, Orion has the leading market position in its home territory, the

Nordic countries.

The subsidiary Fermion produces active pharmaceutical ingredients for both Orion and other pharmaceutical companies. 

Diagnostics business

Orion’s diagnostic tests are used widely around the world to help in diagnosing patients and to contribute to the follow-up of treatment. The emphasis in this product sector is on easy-to-use and rapid point-of-care tests. The leading brand is the QuikRead® CRP test for diagnosing infections.

Read more about products and services here

Read more about Business Divisions here